New discovery suggests opportunity to improve effectiveness of KRAS inhibitors against pancreatic cancer
Mutations in the KRAS gene are the primary driver of pancreatic cancer. A new class of drugs known as KRAS inhibitors is showing initial promise in clinical trials, but many tumors quickly develop resistance to the treatment.
Jul 11, 2024
0
19